Navigation Links
Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
Date:6/10/2008

COPENHAGEN, Denmark, June 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today a Phase I/II study to evaluate a subcutaneous route of administration of ofatumumab (HuMax-CD20(R)) in rheumatoid arthritis (RA) patients, stable on methotrexate will be initiated soon. The study, which will consist of two parts and include approximately 70 patients, will be conducted by GlaxoSmithKline.

"The addition of a subcutaneous method of administrating ofatumumab is a great addition to the ofatumumab development program. We hope this will in future prove to be an advantage to RA patients, who would potentially be able to administer ofatumumab on an outpatient basis," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

Ofatumumab is an investigational drug being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma and rheumatoid arthritis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country.

About the trial This is a two part study. The objective of Part A of the study is to characterize the safety and tolerability of ofatumumab when administered subcutaneously. The primary endpoint is safety and tolerability. The primary endpoint for Part B is to characterize the pharmacokinetics/pharmacodynamics of subcutaneous dosing. Patients in both Part A and Part B are allowed to continue a stable dose methotrexate therapy.

Part A will be a randomized, single-blind, placebo controlled, repeat dose, parallel group, dose-range finding study of approximately 40 patients. Administration of ofatumumab for Part A will occur in a hospital based unit in order to ensure safety.

Part B will be a blinded, randomized, placebo controlled study. On the basis of findings in Part A of the study selected doses will be taken forward for administration in Part B. Dosing for Part B is planned to be conducted
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genmab Announces Updates on Phase III Cancer Studies
2. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
3. Bionomics Achieves US$1 Million Milestone Payment from Genmab
4. DAHANCA Initiates Head and Neck Cancer Study With Genmabs HuMax-EGFr
5. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
6. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
7. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
8. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
9. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
10. Maine Natural Health Company Conducts Dental Clinical Trial
11. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and FARMINGTON, Conn. , ... (NYSE MKT: PTN), a biopharmaceutical company developing targeted, ... with significant unmet medical need and commercial potential, ... private placement of 2,050,000 shares of its common ... shares of its common stock.  Funds under the ...
(Date:12/24/2014)... 23, 2014 Echo Therapeutics, Inc. (NASDAQ: ... focused on skin permeation, continuous glucose monitoring and ... Hollander has been appointed Chief Executive Officer ... than 20 years of experience in the medical ... recently served as Vice President, Business Development, Otsuka ...
(Date:12/24/2014)... , December 24, 2014 ... Report on Global Disposable Syringe Industry of ... its online business intelligence library. ... Disposable Syringe Industry is a professional and ... market.  For overview analysis, the report introduces ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... CHAPEL HILL, N.C., Dec. 17, 2010 The oncology ... by many organizations in the bio-pharmaceutical sector. It,s in ... are scrutinizing their strategies and tactics to support market ... successful launch, it,s critical that companies inform thought leaders, ...
... the growing cholera epidemic in Haiti, the American Red ... the Pan American Health Organization (PAHO) to purchase, ship, ... (Logo: http://photos.prnewswire.com/prnh/20090108/RedCrossLOGO ) ... in Haiti has now exceeded 100,000. Funds will provide ...
Cached Medicine Technology:Research from Best Practices, LLC Delivers Effective Market Education Tactics and Strategies for New Oncology Products 2Red Cross Supports Pan American Health Organization with $1.5 Million in Medicine and Supplies for Cholera Response 2
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... When head lice hits a home or school, ... get rid of it while keeping it from taking over ... have the solution right in their neighborhood: Lice Troopers ... provides full spectrum head lice screening and treatment services to ... Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. ...
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- The risk of ... holidays, so you need to be extra cautious, an ... we see a significant increase in patients coming in ... the Suffolk County Volunteer Firefighters Burn Center of Stony ... should be full of joy, but if not careful, ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch ... and coolest mobile applications on the iOS, Android, and Windows ... NewsWatch, conducted the app review and shared with viewers how ... , The old saying goes, “A picture says a thousand ... can describe a single image, because each picture holds a ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... Milestone in Program to Help Local Producers Grow ... Texas, May 26 Whole Foods Market (Nasdaq: ... organic foods supermarket, announced today that its Local ... United States with $2.5 million in low-interest loans.Whole ...
... 12 times more likely to suffer serious injury, study finds ... million Americans over age 40 have some form of inner-ear ... times more likely to suffer a serious fall, a new ... are unaware of their risk, mostly because they,ve had no ...
... 26, 2009 Babies of East Asian and South Asian ... be misclassified as underweight at birth when compared to their ... Hospital physician Dr. Joel Ray. Dr. Ray and a team ... for these ethnic groups, suggest the need to consider differences ...
... A short, preoperative team briefing prior to cardiac surgery ... improves communication and reduces errors and costs, according to ... researchers believe this is the first such study to ... briefings on specific disruptions to surgery. Disruptions were categorized ...
... May 26 Americans United for Life ... President Barack Obama nominating Sonia Sotomayor to replace Justice ... the President,s talk of finding ,common ground, this appointment ... judicial philosophy undermines common ground. She is a ...
... First Women,s Center of Homestead ORLANDO, Fla., May 26 ... newest restaurant at 2531 NE 8th Street in Homestead, ... Steakhouse to open in Florida and the seventh in ... pre-opening training period, the restaurant recently hosted a Friends ...
Cached Medicine News:Health News:Whole Foods Market(R) Lends $2.5 Million to Local Growers, Producers and Food Artisans 2Health News:Whole Foods Market(R) Lends $2.5 Million to Local Growers, Producers and Food Artisans 3Health News:Inner Ear Dysfunction Puts Older Adults at Risk of Falls 2Health News:Newborns of South Asian and East Asian descent misclassified as underweight at birth: Study 2Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 2Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 3Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 4Health News:LongHorn Steakhouse Brings the Spirit of the West to Homestead 2
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
Inquire...
The Onar®Lp test system is an in vitro test for the qualitative diagnosis of legionella in clinical samples....
... Ventilator is a blower-based, bi-level positive pressure ... patients weighing 30 kg or more. The ... respiratory insufficiency and/or obstructive sleep apnea in ... The KnightStar 330 Ventilator includes a 3-30 ...
Medicine Products: